You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high‐dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma
|
|---|---|
| Published in |
Cancer (0008543X), October 2007
|
| DOI | 10.1002/cncr.23145 |
| Pubmed ID | |
| Authors |
Ulf‐Henrik Mellqvist, Stig Lenhoff, Hans E. Johnsen, Martin Hjorth, Erik Holmberg, Gunnar Juliusson, Jon Magnus Tangen, Jan Westin |
| Abstract |
Today, intensive therapy that includes high-dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexamethasone (VAD) was the most commonly used induction therapy before ASCT and yielded rapid major responses without interfering with stem cell harvest. However, the administration of VAD demands a central venous access, and well-described toxicities are associated with the therapy. This randomized trial, which was initiated in 2001 by the Nordic Myeloma Study Group, was an attempt to bring a larger portion of patients to ASCT more quickly. Patients were randomized to receive either 3 cycles of VAD or 2 courses of cyclophosphamide plus dexamethasone (Cy-Dex) (cyclophosphamide at a dose of 1000 mg/m(2) on Day 1 and dexamethasone at a dose of 40 mg per day on Days 1-4 and 9-12, repeated on Day 22) as initial therapy followed by stem cell mobilization, harvest, and finally ASCT. No significant difference was observed in the proportion of patients undergoing ASCT (VAD [86%] vs Cy-Dex [87%]). During the first 4 months after the initiation of therapy, the mortality rates were 5.8% for VAD and 1.9% for Cy-Dex (P = .08). The response rates after ASCT were comparable (partial response or better: VAD: 80% vs Cy-Dex: 81%). In both groups, the median event-free survival was 29 months, and the overall survival rate at 3 years was 75%. The current results indicated that Cy-Dex before ASCT has efficacy comparable to that of VAD. It also demonstrated that a short course of alkylator therapy using cyclophosphamide does not affect stem cell harvest or transplantation. |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Denmark | 1 | 2% |
| Unknown | 48 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 24% |
| Other | 8 | 16% |
| Student > Bachelor | 5 | 10% |
| Student > Doctoral Student | 4 | 8% |
| Student > Master | 4 | 8% |
| Other | 10 | 20% |
| Unknown | 7 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 52% |
| Agricultural and Biological Sciences | 3 | 6% |
| Unspecified | 2 | 4% |
| Economics, Econometrics and Finance | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Other | 7 | 14% |
| Unknown | 8 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2013.
All research outputs
#8,544,090
of 25,394,764 outputs
Outputs from Cancer (0008543X)
#6,524
of 14,100 outputs
Outputs of similar age
#29,895
of 89,359 outputs
Outputs of similar age from Cancer (0008543X)
#33
of 81 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,100 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 89,359 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.